Skip to main content

Table 4 Repeated measures ANOVA of the selected myocardial injury markers and inflammatory markers

From: Myocardial injury and inflammatory response in percutaneous device closures of pediatric patent ductus arteriosus

Item

Group

preOP

POH6

POH24

POH48

POH72

POH120

WBC (*109/L)

A

6.91 ± 1.26

–

11.52 ± 2.08

12.95 ± 2.58

10.24 ± 1.85

6.70 ± 1.71

 

B

6.27 ± 1.29

–

10.56 ± 1.88

12.52 ± 2.67

9.18 ± 1.76

7.06 ± 1.85

 

C

6.49 ± 1.16

–

11.24 ± 2.09

11.78 ± 1.98

9.86 ± 1.82

7.29 ± 1.60

 

D

6.57 ± 1.29

–

11.42 ± 1.87

11.99 ± 1.96

10.08 ± 2.02

7.20 ± 1.62

 

E

7.25 ± 1.35

–

12.87 ± 2.38abcd

13.10 ± 2.25abcd

10.87 ± 2.02abcd

6.81 ± 1.79

CRP (mg/L)

A

0.40 ± 0.30

–

30.18 ± 22.56

38.83 ± 25.99

19.81 ± 15.13

0.22 ± 0.07

 

B

0.34 ± 0.19

–

28.16 ± 14.02

31.06 ± 17.74

16.93 ± 9.48

0.24 ± 0.07

 

C

0.34 ± 0.21

–

35.09 ± 21.11

33.02 ± 20.20

16.13 ± 8.86

0.25 ± 0.06

 

D

0.39 ± 0.21

–

30.4 ± 18.15

38.87 ± 22.85

19.36 ± 10.34

0.24 ± 0.07

 

E

0.38 ± 0.20

–

56.32 ± 28.92abcd

62.46 ± 31.38abcd

19.07 ± 9.99abc

0.23 ± 0.07

PCT (ng/ml)

A

0.04 ± 0.02

–

5.13 ± 2.38

5.36 ± 2.31

0.25 ± 0.12

0.02 ± 0.01

 

B

0.04 ± 0.03

–

5.06 ± 1.88

5.58 ± 1.95

0.56 ± 0.25

0.02 ± 0.03

 

C

0.04 ± 0.02

–

4.85 ± 2.04

5.73 ± 2.62

0.32 ± 0.12

0.02 ± 0.01

 

D

0.04 ± 0.01

–

4.55 ± 1.68

5.53 ± 2.17

0.31 ± 0.12

0.02 ± 0.05

 

E

0.04 ± 0.02

–

8.22 ± 3.82abcd

9.45 ± 4.40abcd

0.35 ± 0.14abcd

0.02 ± 0.01

IL6 (pg/ml)

A

3.79 ± 1.74

–

74.33 ± 31.70

83.65 ± 37.92

19.86 ± 9.10

4.05 ± 0.56

 

B

3.40 ± 1.63

–

86.17 ± 42.78

82.70 ± 42.11

30.55 ± 14.64

3.98 ± 0.63

 

C

3.57 ± 0.79

–

84.34 ± 25.27

94.09 ± 34.50

15.31 ± 3.40

4.03 ± 0.60

 

D

3.37 ± 1.21

—

85.43 ± 26.47

92.70 ± 21.00

15.72 ± 5.63

4.07 ± 0.61

 

E

3.50 ± 0.76

–

139.88 ± 30.41abcd

96.11 ± 29.59abcd

20.98 ± 4.56abcd

4.04 ± 0.58

CKMB (ug/L)

A

7.52 ± 4.68

8.04 ± 5.11

8.35 ± 4.68

7.46 ± 4.67

–

7.46 ± 4.67

 

B

6.88 ± 4.68

8.74 ± 5.12

7.71 ± 5.13

8.39 ± 4.75

–

8.39 ± 4.75

 

C

7.27 ± 4.87

9.23 ± 4.94

8.35 ± 5.05

8.64 ± 5.05

–

8.64 ± 5.05

 

D

8.00 ± 4.60

7.42 ± 5.24

7.45 ± 4.88

8.09 ± 4.85

–

8.09 ± 4.85

 

E

7.64 ± 4.67

17.67 ± 1.84abcd

20.04 ± 1.49abcd

15.59 ± 1.72abcd

–

7.27 ± 4.77

cTnI (ug/L)

A

0.04 ± 0.02

0.05 ± 0.02

0.06 ± 0.03

0.06 ± 0.03

–

0.06 ± 0.03

 

B

0.05 ± 0.02

0.06 ± 0.02

0.06 ± 0.03

0.05 ± 0.03

–

0.06 ± 0.03

 

C

0.05 ± 0.02

0.05 ± 0.04

0.06 ± 0.03

0.05 ± 0.03

–

0.05 ± 0.03

 

D

0.04 ± 0.02

0.06 ± 0.02

0.06 ± 0.03

0.05 ± 0.02

–

0.06 ± 0.03

 

E

0.04 ± 0.02

0.96 ± 0.54abcd

1.33 ± 0.71abcd

0.88 ± 0.34abcd

–

0.05 ± 0.03

  1. ANOVA, one-way analysis of variance; WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; IL6, inflammatory markers including interleukin-6; CKMB, creatine kinase isoenzyme MB; cTnI, troponin I; preOP, preoperative; POH6, POH24, POH48, POH72, POH120: Postoperative times at 6, 24, 48, 72, and 120 h, respectively
  2. Group A: ligation, Group B: clamping; Group C: ligation combined with suturing; Group D: ligation combined with clamping groups; Group E: device group. Group comparison of repeated measures ANOVA: aGroup A versus Group E; bGroup B versus Group E; cGroup C versus Group E; dGroup D versus Group E; P < 0.001. There was no significant difference between Group A, B, C, D, with all P > 0.05
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us